NovaDel Pharma Inc. is a specialty pharmaceutical company developing oral spray formulations for a range of marketed pharmaceuticals. The Company’s oral spray technology is focused on addressing unmet medical needs for an array of existing and future pharmaceutical products. Its most advanced oral spray candidates target angina, insomnia, erectile dysfunction, migraine headaches, nausea and disorders of the central nervous system. The Company plans to develop these and other products independently and through collaborative arrangements with pharmaceutical and biotechnology companies. In August 2013, Suda Ltd announced that the acquisition of the NovaDel Pharma Inc. assets was completed.